Audio

Rhonda Voskuhl, MD

Publish date: May 19, 2014

Rhonda Voskuhl, MD, describes her investigation into the effect of estriol plus glatiramer acetate on annualized relapse rate in women with relapsing-remitting MS.

 

Recommended Reading

Natalizumab mobilizes latent JC virus in mononuclear cells in MS
MDedge Neurology
Natalizumab reduced biomarkers of intrathecal inflammation in progressive MS
MDedge Neurology
Spinal fluid may help flesh out natalizumab-associated PML diagnosis
MDedge Neurology
B-cell inhibitor might prevent new brain lesions in multiple sclerosis
MDedge Neurology
AAN Finds That Medical Marijuana May Alleviate Certain MS Symptoms
MDedge Neurology
VIDEO: New meds, remyelination therapies move ahead in multiple sclerosis
MDedge Neurology
VIDEO: How to diagnose multiple sclerosis in childhood and adolescence
MDedge Neurology
Proposed neuromyelitis optica diagnostic criteria reflect new disease understanding
MDedge Neurology
New Dose of Glatiramer Acetate May Have Advantages, Compared With Standard Dose
MDedge Neurology
Estriol May Increase Benefits of Treatment With Glatiramer Acetate
MDedge Neurology